Article citationsMore >>

Cornell HJ. Auricchio RS. De Ritis G. Vincenzi M. Maiuri L. Raia V. Silano V. Intestinal mucosa of coeliacs in remission is unable to abolish toxicity of gliadin peptides on in vitro developing fetal rat intestine and cultured atrophic coeliac mucosa. Paediatric Research. 1998; 24: 233-237.

has been cited by the following article:

Article

Enzyme Therapy for Patients with Celiac Disease - An Update

1RMIT University, School at Applied Science, Melbourne, Australia

2Glutagen Pty Ltd, Melbourne, Australia

3Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Tel Hashomer, Israel


International Journal of Celiac Disease. 2021, Vol. 9 No. 1, 28-34
DOI: 10.12691/ijcd-9-1-1
Copyright © 2021 Science and Education Publishing

Cite this paper:
Hugh J. Cornell, Teodor Stelmasiak, Aaron Lerner. Enzyme Therapy for Patients with Celiac Disease - An Update. International Journal of Celiac Disease. 2021; 9(1):28-34. doi: 10.12691/ijcd-9-1-1.

Correspondence to: Teodor  Stelmasiak, Glutagen Pty Ltd, Melbourne, Australia. Email: glutagen@bigpond.com

Abstract

Enzyme therapy as a management tool for patients with celiac disease (CD) or gluten intolerance is gaining acceptance around the world. Gluten has multiple side effects and limitations of a gluten-free diet (GFD) in management of CD are evident and mainly related to the presence of hidden gluten or cross-contamination of meals in restaurants. The present paper discusses enzyme therapy with caricain, namely Gluteguard, in light of various approaches searching for a treatment or an effective management of CD. Regular users of the supplement Gluteguard report a high level of satisfaction with the product. This indicates that enzyme therapy based on caricain has its place as a safeguard when the gluten-free meals are prepared outside the control of the patients.

Keywords